Liu C-Y, Müller M H, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis M E
Department of Surgery, Ludwig-Maximilians University, Hospital Grossharden, Munich, Germany.
Neurogastroenterol Motil. 2004 Dec;16(6):759-64. doi: 10.1111/j.1365-2982.2004.00576.x.
Visceral hypersensitivity in the upper gastrointestinal tract is a potential pathomechanism of functional dyspepsia. The herbal preparation STW 5 (Iberogast) provides symptomatic relief for this condition. We aimed to investigate whether STW 5 modulates intestinal afferent sensitivity.
The herbal preparation STW 5 or vehicle (30.8% ethanol) were administered orally in male Wister rats. After 2 h animals were anaesthetized and extracellular multi-unit intestinal afferent nerve recordings were secured from the neurovascular bundle of the mesentery in the proximal jejunum. Afferent discharge to ramp distension of the intestinal loop (0-60 cm H2O) and dose-response curves for i.v. bradykinin (10, 20 and 40 microg kg(-1)) and 5-HT (5, 10, 20 and 40 microg kg(-1)) were recorded.
Baseline discharge was not different between the vehicle and treatment group. Ramp distension was followed by a pressure dependent increase in afferent nerve discharge that was decreased following STW 5 pretreatment for all distending pressures reaching 147 +/- 8 impulses s(-1) (imp s(-1)) following STW 5 vs 171 +/- 5 imp s(-1) following vehicle at 60 cm H2O (mean +/- SEM; P < 0.05). A dose-dependent increase in afferent discharge was observed for 5-HT and bradykinin. Following STW 5 pretreatment, afferent discharge was reduced at all doses of 5-HT to 110 +/- 5 at the maximum dose after STW 5 and 128 +/- 3 imp s(-1) in controls (all P < 0.05). Afferent discharge to bradykinin was similarly reduced at 20 and 40 microg kg(-1) but not at 10 microg kg(-1) of bradykinin with a discharge rate of 176 +/- 7 imp s(-1) following STW 5 and 200 +/- 6 imp s(-1) in controls at 40 microg kg(-1) (P < 0.05).
The preparation STW 5 reduces intestinal afferent nerve discharge following chemical and mechanical stimuli, while baseline discharge is not affected. This effect of STW 5 on afferent sensitivity may contribute to its therapeutic relief of dyspeptic symptoms.
上消化道内脏高敏感性是功能性消化不良的一种潜在发病机制。草药制剂STW 5（伊贝戈斯特）可缓解这种病症的症状。我们旨在研究STW 5是否能调节肠传入敏感性。
给雄性Wistar大鼠口服草药制剂STW 5或赋形剂（30.8%乙醇）。2小时后将动物麻醉，从空肠近端肠系膜的神经血管束记录细胞外多单位肠传入神经活动。记录肠袢斜坡扩张（0 - 60 cm H₂O）时的传入放电，以及静脉注射缓激肽（10、20和40 μg kg⁻¹）和5-羟色胺（5、10、20和40 μg kg⁻¹）的剂量-反应曲线。
赋形剂组和治疗组的基线放电无差异。斜坡扩张后，传入神经放电随压力增加，在所有扩张压力下，STW 5预处理后传入神经放电减少，在60 cm H₂O时，STW 5处理后为147 ± 8次冲动/秒（imp s⁻¹），赋形剂处理后为171 ± 5 imp s⁻¹（平均值 ± 标准误；P < 0.05）。观察到5-羟色胺和缓激肽使传入放电呈剂量依赖性增加。STW 5预处理后，在所有5-羟色胺剂量下，最大剂量时传入放电降至110 ± 5次，对照组为128 ± 3 imp s⁻¹（所有P < 0.05）。缓激肽剂量为20和40 μg kg⁻¹时，传入放电同样减少，但缓激肽剂量为10 μg kg⁻¹时未减少，40 μg kg⁻¹缓激肽时，STW 5处理后放电率为176 ± 7 imp s⁻¹，对照组为200 ± 6 imp s⁻¹（P < 0.05）。
制剂STW 5可减少化学和机械刺激后的肠传入神经放电，而基线放电不受影响。STW 5对传入敏感性的这种作用可能有助于其对消化不良症状的治疗缓解。
